2017 American Transplant Congress
Effect of Hepatitis C (HCV) Treatment on Rejection Incidence and Severity in Post-Liver Transplant Patients.
Organ Transplant, Scripps Clinic, La Jolla, CA
Introduction: Hepatitis C remains an important source of morbidity and mortality post liver transplant. Little is known about the long term effects of direct acting…2017 American Transplant Congress
Use of Hepatitis C Infected Organs for Kidney Transplantation: A Medical Decision Analysis.
1Dalhousie University, Halifax, NS, Canada; 2University of Alberta, Edmonton, AB, Canada
Given that Hepatitis C (HCV) can be cured, organs from HCV+ deceased donors might be used in HCV- recipients if treatment at the time of…2017 American Transplant Congress
HCV Eradication with DAA Therapy Should Be Attempted Prior to Liver Transplantation and Does Not Impact HCC Recurrence.
University of Alberta, Edmonton, AB, Canada
Background: Recent advances in the direct-acting antiviral (DAA) treatment of HCV have lead to high rates of HCV eradication, even in patients with decompensated cirrhosis.…2017 American Transplant Congress
Occult Hepatitis C Virus in Recipients of Kidney Transplantation: Prevalence and Clinical Implications.
Occult HCV infection (OCI) is characterized by the presence of HCV- RNA in liver or in peripheral blood mononuclear cells in the absence of serological…2017 American Transplant Congress
Liver Allograft Hepatitis and Graft Loss After Hepatitis C Clearance.
Surgery, University of Maryland School of Medicine, Baltimore, MD
Successful HCV therapies should improve inferior outcomes of liver transplantation (LT) for HCV cirrhosis. We hypothesize certain patients may be predisposed to heterologous immunity that…2017 American Transplant Congress
Post Transplant Outcomes in Hepatitis C Positive Patients.
Montefiore Medical Center, Bronx
Hepatitis C (HCV) is associated with increased morbidity and mortality after kidney transplant (KTx). We aimed to assess outcomes of HCV positive patients at our…2017 American Transplant Congress
Transplantation of Hepatitis C Kidneys to Hepatitis C Recipients Confers Significantly Shorter Waiting Times in the Era of the New Kidney Allocation System.
Nashville VA Medical Center, Nashville, TN
Background: Prior to the new KAS, transplantation with HCV+ compared to HCV- kidneys provided shorter waiting times on the deceased donor list. In the current…2016 American Transplant Congress
High Efficacy of Ledipasvir/Sofosbuvir with Ribavirin in HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials.
Introduction: HCV infected patients with decompensated liver disease have significant morbidity & mortality. The efficacy & safety of LDV/SOF + RBV was evaluated in a…2016 American Transplant Congress
Tacrolimus Levels in Patients Treated with Direct Acting Antivirals Post-Transplant.
Pharmacy, Oregon Health & Science University, Portland, OR.
Purpose: To determine if treatment of recurrent hepatitis C virus (HCV) post-liver transplant with the direct-acting antivirals (DAAs) sofosbuvir, simeprevir, and ledipasvir (in combination and/or…2016 American Transplant Congress
Short Duration Perioperative Administration of Ledipasvir/Sofosbuvir Is Safe and Effective in Preventing HCV Recurrence After Liver Transplant.
Background:The optimal timing and duration of DAA therapy in HCV patients undergoing liver transplant(LT) is unknown. CRUSH-C is an open-label, Phase 2 study evaluating the…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 28
- Next Page »